Language selection

Government of Canada / Gouvernement du Canada

Search

Index of Published Newsletters

On this page

For articles that are no longer available online, contact the Health Product InfoWatch Editorial Team.

The Health Product InfoWatch

December 2024

November 2024

October 2024

September 2024

August 2024

July 2024

June 2024

May 2024

April 2024

March 2024

February 2024

January 2024

December 2023

November 2023

October 2023

September 2023

August 2023

July 2023

June 2023

May 2023

April 2023

March 2023

February 2023

January 2023

December 2022

November 2022

October 2022

September 2022

August 2022

July 2022

June 2022

May 2022

April 2022

March 2022

February 2022

January 2022

December 2021

November 2021

October 2021

September 2021

August 2021

July 2021

June 2021

May 2021

April 2021

March 2021

February 2021

January 2021

December 2020

November 2020

October 2020

September 2020

August 2020

July 2020

June 2020

May 2020

April 2020

March 2020

February 2020

January 2020

December 2019

November 2019

October 2019

September 2019

August 2019

July 2019

June 2019

May 2019

April 2019

March 2019

February 2019

January 2019

December 2018

November 2018

October 2018

September 2018

August 2018

July 2018

June 2018

May 2018

April 2018

March 2018

February 2018

January 2018

December 2017

November 2017

October 2017

September 2017

August 2017

July 2017

June 2017

May 2017

April 2017

March 2017

February 2017

January 2017

December 2016

November 2016

October 2016

September 2016

August 2016

July 2016

June 2016

May 2016

April 2016

March 2016

February 2016

January 2016

December 2015

November 2015

October 2015

September 2015

August 2015

July 2015

June 2015

May 2015

April 2015

March 2015

February 2015

January 2015

Canadian Adverse Reaction Newsletters

October 2014; 24(4)

  • Incretin-based therapies and the risk of pancreatic cancer
  • Intravenous methylprednisolone and liver injury
  • Sorafenib and osteonecrosis of the jaw
  • Summary of advisories

July 2014; 24(3)

  • Cisplatin and aortic thrombosis
  • Hydroxychloroquine and hypoglycemia
  • Case presentation: Suspected interaction between ginkgo biloba and efavirenz
  • Summary of advisories

April 2014; 24(2)

  • Quetiapine and acute liver failure
  • Azithromycin and drug reaction with eosinophilia and systemic symptoms
  • Clopidogrel and acquired hemophilia
  • Summary of advisories

January 2014; 24(1)

  • Vascular endothelial growth factor receptor inhibitors and thrombotic microangiopathy
  • Incidents involving the combined use of Durepair Dura Regeneration Matrix with ancillary wound closure products
  • Summary of advisories

October 2013; 23(4)

  • Adverse reaction reports make a difference
  • Summary of advisories

July 2013; 23(3)

  • Oral fluoroquinolones and retinal detachment
  • Adverse reaction and incident reporting-2012
  • Summary of advisories

April 2013; 23(2)

  • Intraocular lenses and the development of glistenings
  • Exenatide: international reports of pancreatic cancer
  • Quarterly Summary of health professional and consumer advisories

January 2013; 23(1)

  • Pico-Salax (sodium picosulfate/magnesium citrate) and convulsions
  • Risperidone and rhabdomyolysis independent of neuroleptic malignant syndrome
  • Docetaxel and serious respiratory-related adverse reactions
  • Case presentation: Ear drops containing peanut oil and suspected association with anaphylaxis
  • Summary of advisories

October 2012; 22(4)

  • Lyme disease test kits and limitations
  • Antiandrogens and hepatotoxicity
  • Case presentation: Thalomid and posterior reversible encephalopathy syndrome
  • Summary of advisories

July 2012; 22(3)

  • LigaSure vessel sealing system and torn vessels
  • CARN is "going green"
  • Adverse reaction and incident reporting -- 2011
  • Summary of advisories

April 2012; 22(2)

  • Minocycline: drug-induced lupus erythematosus and autoimmune hepatitis in adolescents
  • Fentanyl and serotonin syndrome
  • Summary of advisories

January 2012; 22(1)

  • Second-generation antipsychotics and cardiometabolic adverse reactions in children and adolescents
  • Prescription drugs and pediatric patients
  • Canadian Paediatric Surveillance Program
  • Adverse reaction reporting in children: update
  • Adverse reaction reporting form
  • Did you know? The Drug Safety and Effectiveness Network (DSEN) and pediatric projects
  • Summary of advisories

October 2011; 21(4)

  • Custom-Pak Ophthalmic Surgery Procedure Pack: contamination with foreign bodies and risk of related complications
  • Case presentation: Dental/surgical rotary handpieces and patient burns
  • CARN's 20th anniversary
  • Did you know? Medical devices and incidents
  • Summary of advisories

July 2011; 21(3)

  • Proton pump inhibitors: hypomagnesemia accompanied by hypocalcemia and hypokalemia
  • Adverse reaction and incident reporting -- 2010
  • Case presentation: Floseal hemostatic matrix and suspected association with misinterpretation as recurrent malignant disease
  • Risk communication information
  • Summary of advisories

April 2011; 21(2)

  • Fluticasone propionate and osteonecrosis
  • Rosiglitazone-fenofibrate interaction: severe paradoxical decreased high-density lipoprotein cholesterol levels
  • Varenicline and hyperglycemia in patients with diabetes
  • Quinine sulfate and serious adverse reactions
  • Summary of advisories

January 2011; 21(1)

  • Clozapine and life-threatening gastrointestinal hypomotility
  • Case presentation: Bio-Alcamid soft-tissue endoprosthesis and suspected association with late infection
  • Natural health product identification in adverse reaction reports
  • Summary of advisories

October 2010; 20(4)

  • Statins and interstitial lung disease
  • Potential interference of computed tomography(CT) scanning with electronic medical devices
  • Case presentation: Red Bull Energy Drink and suspected association with seizure
  • New consumer form for reporting adverse reactions
  • Summary of advisories

July 2010; 20(3)

  • Pregabalin (Lyrica): suicidal ideation and attempt
  • Adverse incidents with injectable hyaluronic acid dermal fillers
  • Oral iron supplements: skin reactions and other hypersensitivity reactions
  • Summary of advisories

April 2010; 20(2)

  • Leflunomide and peripheral neuropathy
  • Adverse reaction and incident reporting - 2009
  • Summary of advisories

January 2010; 20(1)

  • Black cohosh products and liver toxicity: update
  • Canada Vigilance Online Database
  • Case presentation: Denture adhesive creams and neuropathy
  • Summary of advisories

October 2009; 19(4)

  • Intravenous immune globulin (IVIG): hemolytic reactions
  • Antiviral medications and influenza A (H1N1): reporting adverse reactions
  • Sildenafil (Revatio): medication incident
  • Adverse reaction reporting form
  • Summary of advisories

July 2009; 19(3)

  • Montelukast (Singulair): psychiatric reactions
  • Intravitreal injection of triamcinolone acetonide: ocular reactions
  • Fentanyl transdermal patches and accidental child exposure
  • Summary of advisories

April 2009; 19(2)

  • Atypical antipsychotics and agranulocytosis
  • Adverse reaction and incident reporting - 2008
  • Announcement: Cough and cold products
  • Case presentation: 5-Hour Energy drink and a cardiovascular adverse reaction
  • Adverse reaction reporting form
  • Summary of advisories

January 2009; 19(1)

  • Local anesthetic infusion with pain pumps and chondrolysis
  • Natural health products and adverse reactions: update
  • Case presentation: Propolis and renal failure
  • Summary of advisories

October 2008; 18(4)

  • Botulinum toxin type A and distant toxin spread
  • Case presentation: IVIG and transfusion-related acute lung injury
  • Cesium chloride and ventricular arrhythmias
  • Summary of advisories

July 2008; 18(3)

  • Fentanyl transdermal patch and fatal adverse reactions
  • Atomoxetine and suicidal behaviour: update
  • Twinject auto-injector and device malfunctions
  • Summary of advisories

April 2008; 18(2)

  • Varenicline and serious psychiatric reactions
  • Serious adverse reaction and medication incident
  • Adverse reaction reporting - 2007
  • Summary of advisories

January 2008; 18(1)

  • IVIG: myocardial infarction and cerebrovascular and thrombotic adverse reactions
  • Case presentation: NuvaRing and aortic thrombosis
  • Canada Vigilance Program
  • Evra: myocardial infarction and thromboembolic adverse reactions
  • Summary of advisories

October 2007; 17(4)

  • Gadolinium-containing agents: update on nephrogenic systemic fibrosis
  • Sibutramine and cardiovascular adverse reactions
  • Swedish Adjustable Gastric Band and erosion
  • Summary of advisories

July 2007; 17(3)

  • Benadryl Total: medication incident and stroke
  • Rosiglitazone and parotid gland enlargement: update
  • Adverse reaction reporting: education modules
  • Case presentation: Norethindrone and decreased breast milk production
  • Summary of advisories

April 2007; 17(2)

  • Quetiapine: pancreatitis and thrombocytopenia
  • Case presentation: Telithromycin and toxic epidermal necrolysis
  • Bitter orange (synephrine): update on cardiovascular reactions
  • Adverse reaction reporting - 2006
  • Summary of advisories

January 2007; 17(1)

  • Levofloxacin: dysglycemia and liver disorders
  • Domperidone: heart rate and rhythm disorders
  • Case presentation: Green tea extract and hepatotoxicity
  • Summary of advisories

October 2006; 16(4)

  • BioGlue: chronic inflammation and foreign-body reactions
  • New tool for reporting adverse reactions
  • Physician reporting of adverse reactions
  • Case presentation: Atomoxetine and tics
  • Summary of advisories

July 2006; 16(3)

  • Adverse reactions in children: Why report?
  • Case presentations:
    • Extended-release methylphenidate withdrawal: priapism
    • Iodoquinol: hypertensive encephalopathy and seizures
    • Symposium on drug, food and natural health product interactions
    • Summary of advisories

April 2006; 16(2)

  • Tenofovir and NSAIDs: acute renal failure
  • Adverse reaction reporting - 2005
  • Isotretinoin: myocardial infarction, cerebrovascular and thromboembolic disorders
  • Case presentation: Overnight orthokeratology and Acanthamoeba keratitis
  • Regional Adverse Reaction Centres: relocation
  • Summary of advisories

January 2006; 16(1)

  • Oseltamivir and warfarin: increase in INR
  • Levonorgestrel-releasing intrauterine system and uterine perforation
  • Guidance document for industry
  • Energy drinks
  • Case presentation: Rosiglitazone: parotid gland enlargement
  • Summary of advisories

October 2005; 15(4)

  • Intrathecal baclofen: pump system incidents
  • Statins and memory loss
  • Chloral hydrate and potassium chloride: medication incident
  • Case presentation: Ayurvedic medicines: lead contamination
  • New MedEffect e-notice and Web site
  • Summary of advisories

July 2005; 15(3)

  • Transdermal fentanyl: abuse in adolescents
  • Black cohosh: international reports of liver toxicity
  • Rosiglitazone: decreased HDL cholesterol levels
  • Ibuprofen: Stevens-Johnson syndrome
  • New Regional Adverse Reaction Centres
  • Case presentation: mefloquine with QT prolongation
  • Summary of advisories

April 2005; 15(2)

  • Hylan G-F 20: joint inflammation and pain
  • Adverse reaction reporting - 2004
  • Products derived from bees: serious adverse reactions
  • Case presentation: rhabdomyolysis with clopidogrel, atorvastatin and cyclosporine
  • Summary of advisories

January 2005; 15(1)

  • Telithromycin and warfarin
  • Linezolid and neuropathy
  • Camphor and eucalyptus oils
  • Adverse reaction reporting
  • Natural weight loss product and myopathy
  • Ceftriaxone and immune hemolytic anemia in children
  • Case presentation: olanzapine and pulmonary embolism
  • Summary of advisories

October 2004; 14(4)

  • Transdermal fentanyl (Duragesic): respiratory arrest in adolescents
  • Infliximab (Remicade) and etanercept (Enbrel): serious infections and tuberculosis
  • Bitter orange (synephrine): cardiovascular reactions
  • Case presentations:
    • Ibutilide and torsades de pointes
    • Tubersol and anaphylaxis
  • Summary of advisories

July 2004; 14(3)

  • Fluoroquinolones and warfarin: suspected interactions
  • Suspected warfarin-cranberry juice interaction
  • Case presentations:
    • Tutoplast Dura graft and Creutzfeldt-Jakob disease
    • Toxic shock syndrome and tampons
  • Summary of advisories

April 2004; 14(2)

  • Sterol and sterolin-containing products: hematologic adverse reactions
  • Adverse reaction reporting - 2003
  • Feasibility study of active surveillance of adverse reactions in children
  • Public opinion survey on post-market surveillance
  • Case presentation: clopidogrel
  • Summary of advisories

January 2004; 14(1)

  • Valdecoxib (Bextra™): severe cutaneous reactions
  • Natural health products
  • Case presentations:
    • Ciprofloxacin
    • Finasteride
  • Drug Safety Information Workshop II Report
  • Human growth hormone (somatropin): Prader-Willi syndrome
  • Summary of advisories

October 2003; 13(4)

  • Bisphosphonates and ocular disorders
  • Fluticasone and adrenal suppression
  • Adhesion prevention solutions in gynecological procedures
  • Case presentation: intravenous immunoglobulins
  • Summary of Advisories
  • Insulin products

July 2003; 13(3)

  • Gatifloxacin (Tequin™): hypoglycemia and hyperglycemia
  • Serotonin syndrome
  • Summary of advisories
  • Case presentation: red yeast rice and rhabdomyolysis

April 2003; 13(2)

  • Withdrawal reactions with paroxetine and other SSRIs
  • Adverse reaction reporting - 2002
  • Case presentation: divalproex
  • Safe use of products containing acetaminophen
  • Hormone replacement therapy
  • Summary of advisories

January 2003; 13(1)

  • Suspected hepatobiliary reactions to the newer antidepressants
  • Convulsions and newer-generation antihistamines
  • Drug Safety Information Workshop Report
  • Case presentation: RespirActin
  • Summary of advisories

October 2002; 12(4)

  • Natural Health Products: adverse reactions
  • Leflunomide (Arava): hematologic, hepatic and respiratory reactions
  • Case Presentation: moxifloxacin
  • Summary of Advisories
  • Drugs and grapefruit: interactions

July 2002; 12(3)

  • Pure red cell aplasia and Eprex
  • Glitazones: update on adverse reactions
  • Safety of human insulins
  • Case presentation : Kava
  • Summary of Advisories

April 2002; 12(2)

  • Marketed Health Products Directorate
  • Selective COX-2 inhibitors
  • Summary of advisories
  • Oral sodium phosphates solutions
  • Case presentation
  • Adverse reaction reporting - 2001

January 2002; 12(1)

  • Statins: rhabdomyolysis and myopathy
  • Alendronate: suspected pancreatitis
  • HIV-associated lipodystrophy syndrome: overview and summary of case reports
  • Summary of drug advisories
  • Communiqué - Ibuprofen pediatric oral liquid: gastrointestinal bleeding

October 2001; 11(4)

  • Antitubercular drugs: hepatobiliary reactions
  • Electronic subscription to this Newsletter and drug advisories
  • Health professional advisories
  • Atypical antipsychotics: impaired glucose metabolism
  • Communiqué - Brimonidine (Alphagan) ophthalmic drops: accidental ingestion

July 2001; 11(3)

  • Drug advisories now available on the Web
  • Miconazole-warfarin interaction: increased INR
  • New toll-free numbers to report ADRs
  • Rosiglitazone (Avandia): hepatic, cardiac and hematological reactions
  • Adverse drug reaction reporting - 2000: Part 2
  • Communiqué
    • Orlistat (Xenical) interaction with coumarin derivatives: increased INR
    • Azithromycin (Zithromax): myocardial infarction
    • Drugs of Current Interest

April 2001; 11(2)

  • Adverse drug reaction reporting - 2000: Part 1
  • Antiparkinsonian drugs and "sleep attacks"
  • Rofecoxib (Vioxx): a year in review
  • Communiqué - Warfarin and glucosamine: interaction
  • Drugs of Current Interest

January 2001; 11(1)

  • Thioridazine (Mellaril) and mesoridazine (Serentil): prolongation of the QTc interval
  • Clopidogrel (Plavix): hematological reactions
  • Gentamicin ear drops and ototoxicity: update
  • Drugs of Current Interest

October 2000; 10(4)

  • New influenza drugs: unexpected serious reactions
  • Intravenous RhO [D] immune globulin [human]: suspected hemolytic/renal adverse reactions
  • Abboject® Unit-of-Use Syringe: reports of malfunction
  • Communiqué
    • Glucosamine sulfate: hyperglycemia
    • Ketotifen (Zaditen®): sleep apnea
    • Diclofenac (Voltaren Ophtha®) and ketorolac tromethamine (Acular®): corneal ulceration
  • Drugs of Current Interest

July 2000; 10(3)

  • St. John's wort: harmful drug interaction
  • Olanzapine (Zyprexa): suspected serious reactions
  • Sildenafil (Viagra): cardiac risks
  • New Bureau Name
  • Communiqué
    • Citalopram (Celexa) and clarithromycin (Biaxin): interaction
    • Itraconazole (Sporanox): serum sickness-like disorder
  • Drugs of Current Interest

April 2000; 10(2)

  • Adverse drug reaction reporting - 1999
  • Celecoxib (Celebrex): 1 year later
  • Correction - ticlopidine
  • Communiqué - orlistat (Xenical): pancreatitis
  • Drugs of Current Interest

January 2000; 10(1)

  • Cisapride (Prepulsid): interactions
  • Pemoline (Cylert): market withdrawal
  • Bupropion (Zyban): update
  • Communiqué
    • HIV protease inhibitors: paronychia
    • Gingko biloba: bleeding disorders
  • Drugs of Current Interest

October 1999; 9(4)

  • Serious hematologic reactions associated with ticlopidine - update
  • Leukotriene receptor antagonists: suspected adverse reactions
  • Communiqué - Ropinirole (Requip): sleep disorder

July 1999; 9(3)

  • Alteplase (Activase rt-PA) for acute ischemic stroke
  • Abciximab (ReoPro): risk of acute thrombocytopenia
  • Nefazodone (Serzone) and hepatotoxicity
  • Communiqué - Amlodipine (Norvasc): hearing loss

April 1999; 9(2)

  • Bupropion (Zyban): suspected adverse reactions
  • 1998 ADR Statistics
  • Updates: immune globulin IV products, tolcapone (Tasmar)
  • Communiqué - Olanzapine (Zyprexa): priapism

January 1999; 9(1)

  • Isotretinoin and depression
  • Low-dose ASA and GI Bleeding
  • Guidelines for reporting ADRs
  • Communiqué - azithromycin, pentoxifylline, sertraline and carbamazepine: interaction

October 1998; 8(4)

  • Recent News About Drug Risks
  • New Ontario Regional ADR Centre
  • Discontinuation Reactions Associated With SSRIs
  • Communiqué - amantadine and warfarin, pantoprazole

July 1998; 8(3)

  • Quality Information in Spontaneous Reports
  • Donepezil: Suspected Adverse Reactions
  • Olanzapine: Hematological Reactions
  • Communiqué - valproic acid, cefaclor, latanoprost, protease inhibitors

April 1998; 8(2)

  • Alendronate-induced esophagitis
  • 1997 ADR statistics
  • Communiqué - dorzolamide hydrochloride, hydroxychloroquine sulfate, torvastatin calcium, risperidone, venlafaxine hydrochloride

January 1998; 8(1)

  • Drugs: QT interval prolongation and torsades de pointes
  • Ciprofloxacin use in epileptic patients taking phenytoin
  • Appetite suppressants - update
  • Communiqué - vigabatrin, mefloquine, lamotrigine

October 1997; 7(4)

  • Calcium-channel blockers
  • Azithromycin - severe iatrogenic hepatitis
  • Newsletter survey results
  • Communiqué - protease inhibitors, vigabatrin, terconazole, Fen-phen, heparin, paroxetine

July 1997; 7(3)

  • ACE inhibitors and bronchospasm
  • Interferon beta-1b
  • Radiopharmaceuticals
  • New Expert Advisory Committee on Pharmacovigilance

April 1997; 7(2)

  • Adverse drug reaction reporting - 1996
  • Potential abuse of butorphanol nasal spray
  • Aminoglycoside ear drops and ototoxicity

January 1997; 7(1)

  • Primary pulmonary hypertension and appetite suppressants
  • HIV protease inhibitors and increased bleeding in hemophilia?
  • Erythema multiforme and nifedipine
  • Congenital anomalies and fluconazole

October 1996; 6(4)

  • Cefaclor-associated serum sickness-like reaction
  • Newsletter Assessment - Questionnaire

July 1996; 6(3)

  • Cisapride: Arrhythmia Awareness
  • Midazolam: A Wake-Up Call
  • Clarithromycin: Tooth Discolouration and Smell Alteration

April 1996; 6(2)

  • Metformin: Lactic Acidosis
  • Nefazodone: ADR Profile
  • 1995 Statistics ADR or Product Fault?

January 1996; 6(1)

  • Cotrimoxazole
  • Nicotine Patches and exercise
  • Terbinafine - hepatobiliary reactions
  • SSRIs - hyponatremia

October 1995; 5(4)

  • Update: Fertility Drugs
  • Propofol: Convulsions
  • Contraindications: Dinoprostone
  • Vaginal Gel
  • DOCI List

July 1995; 5(3)

  • Reporting Adverse Drug Reactions
  • Lamotrigine (Lamictal): rashes
  • Drug Names: confusion from two fronts
  • Tiaprofenic Acid: cystitis
  • Ticlopidine: revisited
  • DOCI List

April 1995; 5(2)

  • Zidovudine: Benefits of use during pregnancy
  • Serevent®: Patient warnings must be stressed
  • Fluoroquinolones: Tendonitis
  • Topical Antifungals: Recent switch to over-the-counter
  • Phenazopyridine: Hemolytic anemia

January 1995; 5(1)

  • Risperidone and EPS Sumatriptan and migraine exacerbation
  • Bromocriptine
  • Fertility drug awareness
  • New regional centre for Quebec

October 1994; 4(3)

  • Regional Centres
  • New Drugs - Serzone, Neurontin, Sabril
  • Drugs of current interest

July 1994; 4(2)

  • Editorial Note
  • Terbinafine Herbal preparations

March 1994; 4(1)

  • Rhabdomyolysis and HMG-CoA
  • Reductase Inhibitors
  • Antidepressants and Suicide
  • Help Wanted: Risperdal

November 1993; 3(2)

  • Ticlopidine HCl - Hematological and Liver Effects
  • H1-Antihistamines - Cardiotoxic Effects

August 1993; 3(1)

  • ACE Inhibitors: Renal Effects
  • Sumatriptan Succinate: Chest Pain
  • Nicotine Patches: Update / Inadvertent Exposure

April 1992; 2(1)

  • ADR Program, 1991 Annual Report
  • Case Report: Drug Interactions with Omeprazole
  • Vasospasm with B-Blockers
  • GI Bleeding with Toradol®

August 1991; 1(2)

  • PPSP Workshop Minocycline - Case reports of severe liver and renal reactions
  • ADRs in the Elderly Ciprofloxacin - ADR profile Diclofenac - Hepatic reactions

January 1991; 1(1)

  • Saskatchewan ADR Pilot Project
  • The WHO Connection Working Group on ADR Assessment

Page details

Date modified: